

Richard F Schlenk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4932375/publications.pdf>

Version: 2024-02-01

317
papers

22,568
citations

18465

62
h-index

8852

145
g-index

320
all docs

320
docs citations

320
times ranked

17976
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Classification and Prognosis in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 2209-2221.	13.9	3,067
2	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	13.9	1,628
3	Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 358, 1909-1918.	13.9	1,514
4	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	13.9	1,284
5	Use of Gene-Expression Profiling to Identify Prognostic Subclasses in Adult Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2004, 350, 1605-1616.	13.9	915
6	Prognostic significance of activating <i>FLT3</i> mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. <i>Blood</i> , 2002, 100, 4372-4380.	0.6	794
7	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2349.	3.8	758
8	Targeting <i>FLT3</i> mutations in AML: review of current knowledge and evidence. <i>Leukemia</i> , 2019, 33, 299-312.	3.3	625
9	<i>TP53</i> alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. <i>Blood</i> , 2012, 119, 2114-2121.	0.6	553
10	The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. <i>Blood</i> , 2011, 117, 2137-2145.	0.6	392
11	Monitoring of Minimal Residual Disease in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 2709-2716.	0.8	355
12	The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 579-590.	12.5	352
13	<i>RUNX1</i> Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 1364-1372.	0.8	349
14	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with <i>CEBPA</i> mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for <i>CEBPA</i> double mutant AML as a distinctive disease entity. <i>Blood</i> , 2011, 117, 2469-2475.	0.6	341
15	Prognostic Significance of Partial Tandem Duplications of the <i>MLL</i> Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia Study Group Ulm. <i>Journal of Clinical Oncology</i> , 2002, 20, 3254-3261.	0.8	291
16	Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. <i>Blood</i> , 2006, 108, 3280-3288.	0.6	269
17	Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 3994-4001.	0.8	257
18	How I treat refractory and early relapsed acute myeloid leukemia. <i>Blood</i> , 2015, 126, 319-327.	0.6	245

#	ARTICLE	IF	CITATIONS
19	Precision oncology for acute myeloid leukemia using a knowledge bank approach. <i>Nature Genetics</i> , 2017, 49, 332-340.	9.4	229
20	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. <i>Blood</i> , 2019, 133, 840-851.	0.6	228
21	High <i>EVI1</i> Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities. <i>Journal of Clinical Oncology</i> , 2010, 28, 2101-2107.	0.8	222
22	The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. <i>Cancer</i> , 2006, 106, 112-119.	2.0	221
23	Clinical, Molecular, and Prognostic Significance of WHO Type <i>inv(3)(q21q26.2)/t(3;3)(q21;q26.2)</i> and Various Other 3q Abnormalities in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3890-3898.	0.8	217
24	The genomic landscape of core-binding factor acute myeloid leukemias. <i>Nature Genetics</i> , 2016, 48, 1551-1556.	9.4	215
25	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. <i>Journal of Clinical Oncology</i> , 2010, 28, 4642-4648.	0.8	205
26	Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy. <i>Blood</i> , 2014, 124, 1426-1433.	0.6	204
27	RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. <i>Blood</i> , 2008, 111, 1357-1365.	0.6	202
28	<i>TET2</i> Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1350-1357.	0.8	198
29	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. <i>Haematologica</i> , 2009, 94, 54-60.	1.7	195
30	Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2006, 24, 969-975.	0.8	177
31	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. <i>Blood</i> , 2014, 123, 914-920.	0.6	167
32	Secondary genetic lesions in acute myeloid leukemia with <i>inv(16)</i> or <i>t(16;16)</i> : a study of the German-Austrian AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 170-177.	0.6	164
33	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). <i>Blood</i> , 2013, 121, 4769-4777.	0.6	162
34	Disclosure of Candidate Genes in Acute Myeloid Leukemia With Complex Karyotypes Using Microarray-Based Molecular Characterization. <i>Journal of Clinical Oncology</i> , 2006, 24, 3887-3894.	0.8	141
35	Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. <i>Blood</i> , 2012, 119, 551-558.	0.6	140
36	The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. <i>Blood</i> , 2013, 122, 1576-1582.	0.6	138

#	ARTICLE	IF	CITATIONS
37	Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. <i>Blood</i> , 2010, 115, 636-642.	0.6	137
38	Precision oncology based on omics data: The NCT Heidelberg experience. <i>International Journal of Cancer</i> , 2017, 141, 877-886.	2.3	133
39	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. <i>Blood</i> , 2012, 120, e83-e92.	0.6	131
40	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. <i>Blood</i> , 2020, 135, 371-380.	0.6	127
41	The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesis. <i>Journal of Clinical Investigation</i> , 2007, 117, 1037-1048.	3.9	127
42	Prognostic Impact of Minimal Residual Disease in CBF-MYH11-Positive Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 3724-3729.	0.8	126
43	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. <i>Cancer Discovery</i> , 2021, 11, 2780-2795.	7.7	125
44	The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (mut): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]). <i>Blood</i> , 2015, 126, 6-6.	0.6	104
45	Comparison of Cytogenetic and Molecular Cytogenetic Detection of Chromosome Abnormalities in 240 Consecutive Adult Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 2480-2485.	0.8	98
46	An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. <i>Blood</i> , 2008, 111, 4490-4495.	0.6	94
47	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. <i>Blood</i> , 2021, 137, 3093-3104.	0.6	91
48	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. <i>British Journal of Haematology</i> , 2015, 169, 694-700.	1.2	90
49	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. <i>Haematologica</i> , 2015, 100, 324-330.	1.7	86
50	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. <i>Blood</i> , 2019, 134, 1608-1618.	0.6	85
51	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia—results of the AMLSG 11-08 trial. <i>Leukemia</i> , 2018, 32, 1621-1630.	3.3	81
52	Post-remission therapy for acute myeloid leukemia. <i>Haematologica</i> , 2014, 99, 1663-1670.	1.7	80
53	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	0.8	76
54	Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 316-325.	1.5	75

#	ARTICLE	IF	CITATIONS
55	Management of patients with acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 1277-1294.	3.3	74
56	Gemtuzumab Ozogamicin in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 623-632.	0.8	73
57	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. <i>Blood</i> , 2020, 136, 3041-3050.	0.6	73
58	Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. <i>Blood</i> , 2014, 123, 4027-4036.	0.6	72
59	Circular RNAs of the nucleophosmin (<i>NPM1</i>) gene in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, 2039-2047.	1.7	72
60	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. <i>Leukemia Research</i> , 2014, 38, 57-64.	0.4	68
61	Impact of Pegfilgrastim on Hematological Reconstitution and Incidence of Neutropenic Fever after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukemia: Comparative Analysis between AMLSG 07-04 and the German AML Intergroup Trial.. <i>Blood</i> , 2006, 108, 2020-2020.	0.6	67
62	High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. <i>Blood</i> , 2012, 119, e67-e75.	0.6	66
63	Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 826-833.	1.7	64
64	Targeted Therapy Alone for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 1197-1198.	13.9	61
65	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. <i>Annals of Hematology</i> , 2016, 95, 1931-1942.	0.8	61
66	Rare occurrence of the <i>JAK2</i> V617F mutation in AML subtypes M5, M6, and M7. <i>Blood</i> , 2006, 107, 1242-1243.	0.6	59
67	Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. <i>Nature Medicine</i> , 2020, 26, 992-994.	15.2	56
68	A proof of concept phase I/II pilot trial of <i> LSD1</i> inhibition by tranilcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. <i>Leukemia</i> , 2021, 35, 701-711.	3.3	56
69	Prognostic Importance of Histone Methyltransferase <i>MLL5</i> Expression in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 682-689.	0.8	53
70	HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 187-196.	2.0	51
71	Midostaurin reduces relapse in <i>FLT3</i> -mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. <i>Leukemia</i> , 2021, 35, 2539-2551.	3.3	51
72	Acute myelogenous leukemia in adolescents and young adults. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27089.	0.8	50

#	ARTICLE	IF	CITATIONS
73	Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2009, 16, 98-104.	1.2	49
74	Gemtuzumab ozogamicin in acute myeloid leukemia revisited. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1185-1195.	1.4	46
75	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	3.3	46
76	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. <i>Blood Advances</i> , 2020, 4, 6342-6352.	2.5	45
77	Prognosis of acute myeloid leukemia patients up to 60 years of age exhibiting trisomy 8 within a non-complex karyotype: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. <i>Haematologica</i> , 2007, 92, 763-770.	1.7	44
78	<i>KIT</i> mutations confer a distinct gene expression signature in core binding factor leukaemia. <i>British Journal of Haematology</i> , 2010, 148, 925-937.	1.2	44
79	Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). <i>Journal of Clinical Oncology</i> , 2021, 39, 3318-3327.	0.8	44
80	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	5.7	44
81	Minimal residual disease-directed therapy in acute myeloid leukemia. <i>Blood</i> , 2015, 125, 2331-2335.	0.6	41
82	Autografting with CD34+ peripheral blood stem cells: retained engraftment capability and reduced tumour cell content. <i>British Journal of Haematology</i> , 1999, 104, 382-391.	1.2	40
83	Integrative nucleophosmin mutation-associated microRNA and gene expression pattern analysis identifies novel microRNA - target gene interactions in acute myeloid leukemia. <i>Haematologica</i> , 2011, 96, 1783-1791.	1.7	39
84	Relapsed/refractory acute myeloid leukemia: any progress?. <i>Current Opinion in Oncology</i> , 2017, 29, 467-473.	1.1	39
85	Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. <i>Leukemia</i> , 2020, 34, 1182-1186.	3.3	39
86	Prognostic Gene-Expression Signatures in Adult Acute Myeloid Leukemia with Normal Karyotype.. <i>Blood</i> , 2005, 106, 756-756.	0.6	38
87	Metabolic factors and blood cancers among 578,000 adults in the metabolic syndrome and cancer project (Me-Can). <i>Annals of Hematology</i> , 2012, 91, 1519-1531.	0.8	37
88	Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations. <i>Genes Chromosomes and Cancer</i> , 2005, 42, 427-432.	1.5	36
89	Therapy-related myeloid neoplasms following treatment with radioiodine. <i>Haematologica</i> , 2012, 97, 206-212.	1.7	35
90	Differential DNA Methylation Predicts Response To Combined Treatment Regimens With a DNA Methyltransferase Inhibitor In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 2539-2539.	0.6	35

#	ARTICLE	IF	CITATIONS
91	Clinical relevance of genomic aberrations in homogeneously treated high-risk stage II/III breast cancer patients. <i>International Journal of Cancer</i> , 2001, 93, 80-84.	2.3	34
92	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. <i>Blood Advances</i> , 2020, 4, 4945-4954.	2.5	34
93	The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 1626-34.	1.7	33
94	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at <i>PML</i> and <i>RARA</i> loci. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 726-732.	1.5	32
95	PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17). <i>Clinical Cancer Research</i> , 2013, 19, 2562-2571.	3.2	32
96	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). <i>Blood</i> , 2015, 126, 322-322.	0.6	32
97	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	0.6	32
98	Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 132-144.	1.2	31
99	Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1. <i>Haematologica</i> , 2020, 105, 2440-2447.	1.7	31
100	Therapeutic Potential of Afatinib in <i>NRG1</i> Fusion-Driven Solid Tumors: A Case Series. <i>Oncologist</i> , 2021, 26, 7-16.	1.9	31
101	CD34+ cell selection of peripheral blood progenitor cells using the CliniMACS device for allogeneic transplantation: clinical results in 102 patients. <i>British Journal of Haematology</i> , 2004, 126, 527-535.	1.2	28
102	Development of a real-time RT-PCR assay for the quantification of the most frequent MLL/AF9 fusion types resulting from translocation t(9;11)(p22;q23) in acute myeloid leukemia. <i>Genes Chromosomes and Cancer</i> , 2003, 38, 274-280.	1.5	26
103	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008, 93, 1219-1226.	1.7	23
104	Risk-Adapted Therapy in Younger Adults with Acute Myeloid Leukemia: Results of the AMLHD98A Trial of the AMLSG. <i>Blood</i> , 2006, 108, 14-14.	0.6	23
105	Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: First results from a prospective multicenter German diagnostic study. <i>Leukemia Research</i> , 2013, 37, 900-906.	0.4	22
106	Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy. <i>Haematologica</i> , 2016, 101, 839-845.	1.7	22
107	Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. <i>Epigenetics</i> , 2016, 11, 517-525.	1.3	22
108	Community-driven development of a modified progression-free survival ratio for precision oncology. <i>ESMO Open</i> , 2019, 4, e000583.	2.0	22

#	ARTICLE	IF	CITATIONS
109	Phase I dose-escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019, 184, 1018-1021.	1.2	21
110	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e122-e124.	1.7	20
111	Outcome of older (>=70 years) APL patients frontline treated with or without arsenic trioxide: an International Collaborative Study. <i>Leukemia</i> , 2020, 34, 2333-2341.	3.3	20
112	JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia. <i>Haematologica</i> , 2006, 91, 1569-70.	1.7	20
113	Panobinostat monotherapy and combination therapy in patients with acute myeloid leukemia: results from two clinical trials. <i>Haematologica</i> , 2018, 103, e25-e28.	1.7	19
114	A Face-Aging App for Smoking Cessation in a Waiting Room Setting: Pilot Study in an HIV Outpatient Clinic. <i>Journal of Medical Internet Research</i> , 2018, 20, e10976.	2.1	19
115	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia: Results of the AMLSG 07-04 Randomized Treatment Trial. <i>Blood</i> , 2011, 118, 80-80.	0.6	18
116	ATRA and Arsenic Trioxide (ATO) Versus ATRA and Idarubicin (AIDA) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia (APL): Results of the Phase III, Prospective, Randomized, Intergroup APL0406 Study by the Italian-German Cooperative Groups Gimema-SAL-AMLSG. <i>Blood</i> , 2012, 120, 6-6.	0.6	18
117	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. <i>Blood</i> , 2016, 128, 449-449.	0.6	18
118	Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 1177-1189.	1.3	17
119	Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 85, 106197.	0.4	16
120	Phase I/II Study of Volasertib (BI 6727), An Intravenous Polo-Like Kinase (Plk) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Updated Results of the Dose Finding Phase I Part for Volasertib in Combination with Low-Dose Cytarabine (LD-Ara-C) and As Monotherapy in Relapsed/Refractory AML. <i>Blood</i> , 2011, 118, 1549-1549.	0.6	16
121	Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation. <i>Journal of Nuclear Medicine</i> , 2006, 47, 278-86.	2.8	16
122	Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study. <i>Haematologica</i> , 2020, 105, 161-169.	1.7	15
123	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	1.2	15
124	Anti-CD123 Targeted Therapy with Talacotuzumab in Advanced MDS and AML after Failing Hypomethylating Agents - Final Results of the Samba Trial. <i>Blood</i> , 2018, 132, 4045-4045.	0.6	15
125	Continued Low-Dose Decitabine (DAC) Is an Active First-Line Treatment of Older AML Patients: First Results of a Multicenter Phase II Study. <i>Blood</i> , 2005, 106, 1852-1852.	0.6	15
126	Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study. <i>Haematologica</i> , 2006, 91, 285-6.	1.7	15

#	ARTICLE	IF	CITATIONS
127	Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. <i>Haematologica</i> , 2021, 106, 3100-3106.	1.7	14
128	Phase 2 Study of Monotherapy Galunisertib (LY2157299 Monohydrate) in Very Low-, Low-, and Intermediate-Risk Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 1669-1669.	0.6	14
129	CDK4/6 Inhibitor Palbociclib for Treatment of KMT2A-Rearranged Acute Myeloid Leukemia: Interim Analysis of the AMLSG 23-14 Trial. <i>Blood</i> , 2016, 128, 1608-1608.	0.6	14
130	Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML): Results of the AML Study Group (AMLSG). <i>Blood</i> , 2008, 112, 699-699.	0.6	14
131	Diagnostic value of fluorescence in situ hybridization for the detection of genomic aberrations in older patients with acute myeloid leukemia. <i>Haematologica</i> , 2005, 90, 194-9.	1.7	14
132	Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. <i>BMJ Open</i> , 2020, 10, e039639.	0.8	13
133	Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 In Combination with Low-Dose Cytarabine. <i>Blood</i> , 2010, 116, 3316-3316.	0.6	13
134	Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications. <i>Blood</i> , 2010, 116, 909-909.	0.6	13
135	Prospective Multicenter Phase 3 Study Comparing 5-Azacytidine (5-Aza) Induction Followed By Allogeneic Stem Cell Transplantation Versus Continuous 5-Aza According to Donor Availability in Elderly MDS Patients (55-70 years) (VidazaAllo Study). <i>Blood</i> , 2018, 132, 208-208.	0.6	12
136	Gene Mutations as Predictive Markers for Postremission Therapy in Younger Adults with Normal Karyotype AML. <i>Blood</i> , 2006, 108, 4-4.	0.6	12
137	Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. <i>Oncotarget</i> , 2016, 7, 49539-49551.	0.8	12
138	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. <i>Leukemia and Lymphoma</i> , 2014, 55, 2114-2119.	0.6	11
139	Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. <i>Haematologica</i> , 2014, 99, e133-e135.	1.7	11
140	TET2 Mutations In Acute Myeloid Leukemia (AML): Results on 783 Patients Treated within the AML HD98A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2010, 116, 97-97.	0.6	11
141	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. <i>Blood</i> , 2016, 128, 589-589.	0.6	11
142	Aberrant Expression of the Homeobox Gene CDX2 in Acute Myeloid Leukemia. <i>Blood</i> , 2006, 108, 8-8.	0.6	11
143	What's new in consolidation therapy in AML?. <i>Seminars in Hematology</i> , 2019, 56, 96-101.	1.8	10
144	In Acute Myeloid Leukemia with Complex Karyotype TP53 Alterations Are Associated with Specific Genomic Aberrations and Predict Inferior Survival. <i>Blood</i> , 2009, 114, 2632-2632.	0.6	10

#	ARTICLE	IF	CITATIONS
145	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSC). <i>Blood</i> , 2016, 128, 1207-1207.	0.6	10
146	Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials. <i>Oncology Research and Treatment</i> , 2007, 30, 657-662.	0.8	9
147	Cost-effectiveness of methods in personalized medicine. Results of a decision-analytic model in patients with acute myeloid leukemia with normal karyotype. <i>Leukemia Research</i> , 2017, 62, 84-90.	0.4	9
148	Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.. <i>Blood</i> , 2007, 110, 1806-1806.	0.6	9
149	NOTCH1 Mutation and Treatment Outcome In CLL Patients Treated With Chlorambucil (Chl) Or Ofatumumab-Chl (O-Chl): Results From The Phase III Study Complement 1 (OMB110911). <i>Blood</i> , 2013, 122, 527-527.	0.6	9
150	A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. <i>Blood</i> , 2015, 126, 826-826.	0.6	9
151	Pretreatment Cytogenetic Abnormalities Are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients >60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia.. <i>Blood</i> , 2005, 106, 3293-3293.	0.6	9
152	Pathogenic complexity of gastric B-cell lymphoma. <i>Blood</i> , 2002, 100, 1095-1097.	0.6	8
153	Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1369-1380.	1.4	8
154	Requirement for LIM kinases in acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 3173-3185.	3.3	8
155	Phase I/II Study of BI 2536, An Intravenous Polo-Like Kinase-1 (Plk-1) Inhibitor, in Elderly Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML): First Results of a Multi-Center Trial. <i>Blood</i> , 2008, 112, 2973-2973.	0.6	8
156	Is there justification for 4 cycles of consolidation therapy in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 341-344.	0.7	7
157	MicroRNA expression-based outcome prediction in acute myeloid leukemia: novel insights through cross-platform integrative analyses. <i>Haematologica</i> , 2016, 101, e454-e456.	1.7	7
158	Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial. <i>Annals of Hematology</i> , 2017, 96, 887-894.	0.8	7
159	The Genotype NPM1mut/FLT3-ITDneg Is a Highly Significant Predictive Factor for Response to Therapy with All-Trans Retinoic Acid in Acute Myeloid Leukemia - Results from AMLSG Trial AML HD98B.. <i>Blood</i> , 2007, 110, 297-297.	0.6	7
160	Decitabine Response Associated Gene Expression Patterns In Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 3756-3756.	0.6	7
161	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 3744-3744.	0.6	7
162	Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 95163-95175.	0.8	7

#	ARTICLE	IF	CITATIONS
163	Gene Expression Profiling Identifies Distinct Subclasses in Core Binding Factor Acute Myeloid Leukemia.. Blood, 2005, 106, 673-673.	0.6	7
164	Acute Myeloid Leukemia (AML) with 9q Aberrations Occuring within a Non-Complex Karyotype Is Highly Associated with CEBPA and NPM1 Mutations - A Joint Analysis of the German-Austrian AML Study Group (AMLSG) and Cancer and Leukemia Group B (CALGB).. Blood, 2007, 110, 762-762.	0.6	7
165	Molecular characterization of AML with ins(21;8)(q22;q22q22) reveals similarity to t(8;21) AML. Genes Chromosomes and Cancer, 2011, 50, 51-58.	1.5	6
166	Adjusting Simon's optimal two-stage design for heterogeneous populations based on stratification or using historical controls. Biometrical Journal, 2020, 62, 311-329.	0.6	6
167	Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).. Blood, 2009, 114, 945-945.	0.6	6
168	Pharmacodynamic Monitoring of the Efficacy of a Targeted Therapy with Midostaurin By Plasma Inhibitor Activity (PIA) Analysis in FLT3 -ITD Positive AML Patients within the AMLSG 16-10 Trial: A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 2585-2585.	0.6	6
169	Clinical impact of <scp>KMT</scp>2C and <scp>SPRY</scp>4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 2017, 99, 544-552.	1.1	5
170	A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia. British Journal of Haematology, 2019, 185, 583-587.	1.2	5
171	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica, 2021, 106, 2986-2989.	1.7	5
172	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. Blood Advances, 2021, 5, 4370-4379.	2.5	5
173	Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653). Blood, 2012, 120, 1483-1483.	0.6	5
174	Improved Outcome with ATRA-Arsenic Trioxide Compared to ATRA-Chemotherapy in Non-High Risk Acute Promyelocytic Leukemia â€“ Updated Results of the Italian-German APL0406 Trial on the Extended Final Series. Blood, 2014, 124, 12-12.	0.6	5
175	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	0.6	5
176	Ruxolitinib Plus Pomalidomide in Myelofibrosis: Updated Results from the Mpnsg-0212 Trial (NCT01644110). Blood, 2016, 128, 1939-1939.	0.6	5
177	Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia. Blood, 2016, 128, 337-337.	0.6	5
178	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. Blood, 2016, 128, 4271-4271.	0.6	5
179	Identifying Prognostic SNPs in Clinical Cohorts: Complementing Univariate Analyses by Resampling and Multivariable Modeling. PLoS ONE, 2016, 11, e0155226.	1.1	5
180	Expression of the nuclear oncogene Ski in patients with acute myeloid leukemia treated with all-trans retinoic acid. Haematologica, 2008, 93, 1105-1107.	1.7	4

#	ARTICLE	IF	CITATIONS
181	Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study. <i>Haematologica</i> , 2019, 104, e63-e64.	1.7	4
182	Ruxolitinib is effective in the treatment of a patient with refractory T-ALL. <i>EJHaem</i> , 2021, 2, 139-142.	0.4	4
183	Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial. <i>Blood</i> , 2018, 132, 720-720.	0.6	4
184	Postremission Therapy with an Allogeneic Transplantation from an HLA-Matched Family Donor Seems To Overcome the Negative Prognostic Impact of FLT3-ITD in Younger Patients with Acute Myeloid Leukemia Exhibiting a Normal Karyotype. <i>Blood</i> , 2005, 106, 2353-2353.	0.6	4
185	Valproic Acid as Adjunct to Induction Therapy in Patients with Acute Myeloid Leukemia: First Results of Two Randomized Studies of the AMLSG. <i>Blood</i> , 2005, 106, 2800-2800.	0.6	4
186	TP53 Alterations in Acute Myeloid Leukemia with Complex Karyotype Correlate with Specific Copy Number Alterations, Monosomal Karyotype, and Dismal Outcome. <i>Blood</i> , 2011, 118, 3558-3558.	0.6	4
187	Gene Mutations and Treatment Outcome in CLL Patients Treated with Chlorambucil (Chl) or Ofatumumab-Chl (O-Chl): Results from the Phase III Study COMPLEMENT1 (OMB110911). <i>Blood</i> , 2014, 124, 1992-1992.	0.6	4
188	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). <i>Blood</i> , 2015, 126, 226-226.	0.6	4
189	Long-Term Interferon- α Treatment in Essential Thrombocythemia. <i>Blood</i> , 2015, 126, 4064-4064.	0.6	4
190	A new option for remission induction in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2018, 19, 156-157.	5.1	3
191	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. <i>Blood</i> , 2018, 132, 1501-1501.	0.6	3
192	Interim Results of a First in Man Study with the Fc-Optimized FLT3 Antibody Flsyn for Treatment of Acute Myeloid Leukemia with Minimal Residual Disease. <i>Blood</i> , 2019, 134, 3928-3928.	0.6	3
193	Role of Etoposide in Combination with All-Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation. <i>Blood</i> , 2008, 112, 559-559.	0.6	3
194	Determination of the Maximum Tolerated Dose of Panobinostat in Combination with Cytarabine and Mitoxantrone As Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 423-423.	0.6	3
195	Azacitidine-Containing Induction Regimens Followed by Azacitidine Maintenance Therapy in High Risk Acute Myeloid Leukemia: First Results of the Randomized Phase-II AMLSG 12-09 Study (ClinicalTrials.gov) Tj ETQq1d.0.784334 rgBT /	0.6	3
196	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. <i>Blood</i> , 2013, 122, 1283-1283.	0.6	3
197	Polo-Like Kinase-1 (Plk-1) Inhibitor BI 2536 Induces Mitotic Arrest and Apoptosis in Vivo: First Demonstration of Target Inhibition in the Bone Marrow of AML Patients. <i>Blood</i> , 2008, 112, 2641-2641.	0.6	3
198	Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics. <i>Cancer Management and Research</i> , 2011, 3, 157-75.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study. <i>Blood</i> , 2021, 138, 4418-4418.	0.6	3
200	Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSCG CIARA trial). <i>British Journal of Haematology</i> , 2018, 183, 235-241.	1.2	2
201	Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3-ITD: Results from an International Collaboration. <i>Blood</i> , 2019, 134, 2693-2693.	0.6	2
202	Prognosis of Adult Patients ≥ 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the AML-SG and SHG-Dresden Study Groups. <i>Blood</i> , 2005, 106, 2360-2360.	0.6	2
203	Characterization of NPM1-Mutated/FLT3 ITD-Negative Acute Myeloid Leukemia with Normal Karyotype by Gene Expression Profiling. <i>Blood</i> , 2006, 108, 155-155.	0.6	2
204	Prognosis of Adult Patients ≥ 60 Years with AML and Aberrations of Chromosome 11q23: Pooled Data Analysis of the German AML-Intergroup. <i>Blood</i> , 2006, 108, 16-16.	0.6	2
205	Clinical Impact of WT1 Mutations in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia (AML): A Study of the German-Austrian AML Study Group (AMLSCG). <i>Blood</i> , 2007, 110, 364-364.	0.6	2
206	Interim Results of a Phase I/II Clinical Trial of Belinostat in Combination with Idarubicin in Patients with AML Not Suitable for Standard Intensive Therapy. <i>Blood</i> , 2008, 112, 1953-1953.	0.6	2
207	Type and Number of Secondary Molecular Lesions Improve Outcome Prediction in Acute Myeloid Leukemia (AML) with inv(16) or t(16;16): A Study of the German-Austrian AML Study Group (AMLSCG). <i>Blood</i> , 2009, 114, 824-824.	0.6	2
208	A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML. <i>Blood</i> , 2010, 116, 3285-3285.	0.6	2
209	CD34+ FISH As a New Method for Molecular-Cytogenetic Diagnostic From Peripheral Blood in MDS: Update of the Multicenter German Prospective Diagnostic Study. <i>Blood</i> , 2012, 120, 3816-3816.	0.6	2
210	Monitoring By Chromosome Banding Analysis (CBA) and FISH Of Circulating CD34+ Cells In Low-Risk MDS Patients Treated In The Le-Mon-5 Study With Lenalidomide Monotherapy Reveals 82% Cytogenetic Responders With Different Response " , Evolutionary -, and Remission Patterns and No Increased Karyotype Evolution (KE). <i>Blood</i> , 2013, 122, 2783-2783.	0.6	2
211	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. <i>Blood</i> , 2015, 126, 803-803.	0.6	2
212	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2016, 128, 112-112.	0.6	2
213	Open-Label, Multi-Center Phase I Dose Escalation Study with Lenalidomide In Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 3297-3297.	0.6	2
214	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSCG, Cetlam and Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2014, 124, 324-324.	0.6	2
215	Randomized Phase II Study of All- <i>Trans</i> Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of <i>TP53</i> Status. <i>Blood</i> , 2021, 138, 2380-2380.	0.6	2
216	Improving consolidation therapy in acute myeloid leukemia - a tough nut to crack. <i>Haematologica</i> , 2018, 103, 1579-1581.	1.7	1

#	ARTICLE	IF	CITATIONS
217	Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q). <i>Annals of Hematology</i> , 2021, 100, 1463-1471.	0.8	1
218	CEBPA Germline Mutation Screening in Cytogenetically Normal Acute Myeloid Leukemia with Somatic Acquired CEBPA Mutations.. <i>Blood</i> , 2007, 110, 363-363.	0.6	1
219	Combined Analysis of Valproic Acid Induced MicroRNA and Gene Expression Changes in Acute Myeloid Leukemia.. <i>Blood</i> , 2007, 110, 869-869.	0.6	1
220	RUNX1 Mutations in Acute Myeloid Leukemia (AML): Correlation with Distinct Cytogenetic Subgroups and Clinical Outcome. Results of the AML Study Group (AMLSCG). <i>Blood</i> , 2008, 112, 145-145.	0.6	1
221	Analysis of the ETS Family Member Genes ERG, ETS2, ETS1 and FLI1 in Acute Myeloid Leukemia (AML) Patients with Normal Cytogenetics: Expression Levels and Impact On Clinical Outcome. A Study of the AMLSCG.. <i>Blood</i> , 2009, 114, 1600-1600.	0.6	1
222	Mutations of EZH2 In Myeloproliferative Neoplasms with Myelofibrosis: Correlation with Molecular and Clinical Data. <i>Blood</i> , 2010, 116, 4111-4111.	0.6	1
223	ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSCG. <i>Blood</i> , 2011, 118, 412-412.	0.6	1
224	DNMT3A mutations Predict for Inferior Outcome in NPM1-Wildtype and Molecular Unfavorable Cytogenetically-Normal Acute Myeloid Leukemia: A Study of the German-Austrian AMLSCG. <i>Blood</i> , 2011, 118, 415-415.	0.6	1
225	Molecular Characterization Of Myelofibrosis Patients With Cytopenia Treated With Pomalidomide: Results From The Mpnsg 01-09 Study. <i>Blood</i> , 2013, 122, 4064-4064.	0.6	1
226	Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 1381-1381.	0.6	1
227	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2586-2586.	0.6	1
228	Application of a Short Tandem Repeat Based PCR Assay for Chronological Monitoring of Myelodysplastic Syndrome (MDS) Patients with Deletion of Chromosome 5q Following Lenalidomide Treatment. <i>Blood</i> , 2015, 126, 2891-2891.	0.6	1
229	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSCG). <i>Blood</i> , 2015, 126, 3818-3818.	0.6	1
230	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. <i>Blood</i> , 2015, 126, 85-85.	0.6	1
231	Detection of RAS, KIT and FLT3 Gene Mutations in t(8;21)-Positive Acute Myeloid Leukemia (AML): Evaluation of the Clinical Relevance.. <i>Blood</i> , 2006, 108, 2301-2301.	0.6	1
232	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSCG.. <i>Blood</i> , 2006, 108, 1949-1949.	0.6	1
233	RAS, KIT and FLT3 Gene Mutations in inv(16)/t(16;16)-Positive Acute Myeloid Leukemia (AML): Incidence and Relevance on Clinical Outcome.. <i>Blood</i> , 2006, 108, 2303-2303.	0.6	1
234	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSCG 05-04 Trial.. <i>Blood</i> , 2007, 110, 1837-1837.	0.6	1

#	ARTICLE	IF	CITATIONS
235	Prognostic Factors in Adult Patients up to 60 Years with AML and Translocations of Chromosome 11q23: Individual Patient Data Based Analysis of the German AML-Intergroup.. Blood, 2007, 110, 759-759.	0.6	1
236	High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups.. Blood, 2009, 114, 582-582.	0.6	1
237	Mutations in the Fms-Related Tyrosine Kinase 3 (FLT3) Gene Independently Predict Poor Outcome in Acute Myeloid Leukemia (AML) with t(8;21): A Study of the German-Austrian AML Study Group (AMLSG).. Blood, 2009, 114, 825-825.	0.6	1
238	Identification of Clinically Relevant Predictive MRD Checkpoints in AML Patients with NPM1 Mutations: A Study of the AML Study Group (AMLSG).. Blood, 2009, 114, 1586-1586.	0.6	1
239	Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study. Blood, 2010, 116, 185-185.	0.6	1
240	AC220, a Potent Second Generation Class I/III Tyrosine Kinase Inhibitor, Displays a Distinct Inhibition Profile on Mutant-FLT3 as Well as -KIT Isoforms. Blood, 2010, 116, 291-291.	0.6	1
241	NF1 Alterations Are Common In AML with Complex Karyotype and Correlate with Specific Genomic Imbalances. Blood, 2010, 116, 4179-4179.	0.6	1
242	Prediction of Non-Relapse Mortality in Recipients of Reduced Intensity Conditioning Allo-HSCT with Acute Myeloid Leukemia in First Complete Remission: Integrating the Seattle Comorbidity Index (HCT-CI) and EBMT Scoring Systems. Blood, 2012, 120, 734-734.	0.6	1
243	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood, 2012, 120, 46-46.	0.6	1
244	A Multicenter Phase-Ib/II Study of Ruxolitinib/Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis: Safety Data from the MpnsG-0212 Trial (NCT01644110). Blood, 2014, 124, 3161-3161.	0.6	1
245	Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry. Blood, 2016, 128, 2815-2815.	0.6	1
246	Outcome after Inotuzumab Ozogamicin for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia and Extramedullary Disease. Blood, 2021, 138, 3404-3404.	0.6	1
247	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	0.6	1
248	Leukemic Stem Cells of Monocytic AMLs Are Not-Resistant to BCL-2 Inhibition. Blood, 2021, 138, 3469-3469.	0.6	1
249	Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA. Journal of Medical Genetics, 2017, 54, 640-650.	1.5	0
250	MLL/AF9 Fusion Transcript Quantification in t(9;11)-Positive AML Identify Patients with High Risk of Relapse.. Blood, 2004, 104, 3015-3015.	0.6	0
251	Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia Based on Gene Expression Profiling.. Blood, 2004, 104, 2037-2037.	0.6	0
252	Acute Myeloid Leukemia with Deletion 9q Is Associated with CEBPA Loss-of-Function Mutations.. Blood, 2004, 104, 2896-2896.	0.6	0

#	ARTICLE	IF	CITATIONS
253	Pooled Data Analysis of Acute Myeloid Leukemia Patients ≤ 60 Years with Trisomy 8 Treated within the Studies of the German Acute Myeloid Leukemia Intergroup.. Blood, 2005, 106, 2374-2374.	0.6	0
254	Allogeneic Transplantation from an HLA-Matched Family Donor in First Complete Remission of Acute Myeloid Leukemia Had an Adverse Impact on Quality of Life in Patients Followed for at Least Five Years after Treatment: A Survey of the German AML Intergroup on 525 Patients.. Blood, 2005, 106, 747-747.	0.6	0
255	All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.. Blood, 2005, 106, 1849-1849.	0.6	0
256	Comparison of HLA-Identical Sibling Hematopoietic Stem Cell Transplant (HCT) Versus Chemotherapy as Postremission Therapy in t(8;21) Acute Myeloid Leukemia (AML).. Blood, 2005, 106, 1138-1138.	0.6	0
257	Impact of Different Postremission Strategies in Younger Adults with Acute Myeloid Leukemia and Normal Karyotype Exhibiting a CEBPA Mutation.. Blood, 2005, 106, 2352-2352.	0.6	0
258	A FLT3 Gene-Expression Signature Outperforms FLT3 Status in Predicting Clinical Outcome for Patients with Normal Karyotype AML.. Blood, 2006, 108, 2311-2311.	0.6	0
259	Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) Correlated with Specific T Cell Responses and Survival.. Blood, 2006, 108, 414-414.	0.6	0
260	In Vitro and In Vivo Monitoring of Valproic Acid Effects on Gene Expression Signatures in Adult Acute Myeloid Leukemia.. Blood, 2006, 108, 2605-2605.	0.6	0
261	Minimal Residual Disease (MRD) Monitoring in CBF-MYH11 Acute Myeloid Leukemia (AML) Is of Prognostic Relevance for Relapse-Free Survival.. Blood, 2006, 108, 2298-2298.	0.6	0
262	Prognostic Impact of BAALC Expression in the Context of Other Molecular Markers in Cytogenetically Normal Acute Myeloid Leukemia.. Blood, 2007, 110, 3485-3485.	0.6	0
263	Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.. Blood, 2007, 110, 1446-1446.	0.6	0
264	Impact of Pegfilgrastim and Dosing Schedule of Cytarabine on Hematological Reconstitution Times, Incidences of Severe Infection and Duration of Hospitalization after Consolidation Therapy with High-Dose Cytarabine in Acute Myeloid Leukaemia - Interim Results from AMLSG 07-04 Trial.. Blood, 2007, 110, 1836-1836.	0.6	0
265	KIT Mutations Define Characteristic Gene Expression Signatures in Core Binding Factor Leukemias.. Blood, 2007, 110, 3163-3163.	0.6	0
266	The Impact of Therapy-Related and Secondary AML in Relation to Karyotype and Molecular Markers: A Study of the AMLSG.. Blood, 2007, 110, 881-881.	0.6	0
267	Prognostic Implication of Insertion of FLT3 Internal Tandem Duplication in the BETA-1-Sheet of the Tyrosine Kinase Domain-1. Blood, 2008, 112, 2514-2514.	0.6	0
268	Impact of Gene Expression Profiling on Diagnosis and Prognostication in Cytogenetically Normal AML.. Blood, 2008, 112, 1487-1487.	0.6	0
269	Distinct Expression Patterns in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) Characterized by Uniparental Disomy.. Blood, 2008, 112, 1193-1193.	0.6	0
270	Treatment-Related AML Is An Independent Adverse Prognostic Factor for Relapse-Free and Overall Survival. An Analysis of 2,868 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. Blood, 2009, 114, 578-578.	0.6	0

#	ARTICLE	IF	CITATIONS
271	Secondary AML After a History of Myelodysplastic Syndrome Is An Independent Adverse Prognostic Factor for Achievement of Complete Remission, Relapse-Free and Overall Survival. An Analysis of 2,819 Adult Patients with Newly Diagnosed AML Enrolled On Seven AMLSG Treatment Trials.. Blood, 2009, 114, 2621-2621.	0.6	0
272	Deregulated Apoptotic Pathways Point to Effectiveness of IAP Inhibitor Therapy in Acute Myeloid Leukemia.. Blood, 2009, 114, 1275-1275.	0.6	0
273	Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.. Blood, 2009, 114, 2391-2391.	0.6	0
274	Gene Expression Analysis of Independent Data Sets Identifies HBG1 to Be Associated with Outcome in Cytogenetically Normal AML.. Blood, 2009, 114, 2613-2613.	0.6	0
275	Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. Blood, 2010, 116, 2184-2184.	0.6	0
276	A Phase Ib Dose-Finding Study of Oral Panobinostat In Combination with Cytarabine (ara-C) and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia (AML). Blood, 2010, 116, 3310-3310.	0.6	0
277	Isocitrate Dehydrogenase Gene Mutations In Elderly Patients with Acute Myeloid Leukemia (AML) and Outcome After Treatment with All-Trans Retinoic Acid: A Study of the German-Austrian AML Study Group (AMSLG). Blood, 2010, 116, 101-101.	0.6	0
278	High-Resolution Genomic Profiling of Adult and Pediatric Core Binding Factor Acute Myeloid Leukemia Reveals New Recurrent Genomic Aberrations. Blood, 2010, 116, 849-849.	0.6	0
279	Acute Myeloid Leukemia (AML): Prospective Comparison of Different Treatments with a Common Standard Treatment - A Study by the German AML Intergroup. Blood, 2010, 116, 2175-2175.	0.6	0
280	Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification. Blood, 2010, 116, 1693-1693.	0.6	0
281	Assessment of Clonal Evolution in 42 AML with NPM1 Mutations by Molecular Characterization of Paired Diagnosis and Relapse Samples. Blood, 2011, 118, 237-237.	0.6	0
282	Integrative Genomics Approaches Identify Novel Disease-Related Genetic Aberrations in Acute Myeloid Leukemia. Blood, 2011, 118, 402-402.	0.6	0
283	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. Blood, 2011, 118, 1533-1533.	0.6	0
284	Genome-Wide Genotyping of Acute Myeloid Leukemia with t(9;11) Reveals New Recurrent Genomic Alterations,. Blood, 2011, 118, 3546-3546.	0.6	0
285	Deregulated Expression of EVI1 Defines a Poor Prognostic Subset of MLL-Rearranged Acute Myeloid Leukemias. Blood, 2011, 118, 1441-1441.	0.6	0
286	Genome Wide DNA Methylation Analysis of Patients with Myelodysplastic Syndrome and Isolated Deletion (5q) Reveals Characteristic Methylation Profiles in Low and Intermediate-1 Risk Groups. Blood, 2012, 120, 3801-3801.	0.6	0
287	Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01â€™09 Study (ClinicalTrials.gov Identifier: NCT00949364).. Blood, 2012, 120, 2840-2840.	0.6	0
288	Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication. Blood, 2012, 120, 785-785.	0.6	0

#	ARTICLE	IF	CITATIONS
289	The Nucleophosmin-1 Splice Variant Analysis Provides More Important Information On Prognosis Than NPM1 Mutational Status In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 2563-2563.	0.6	0
290	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. <i>Blood</i> , 2013, 122, 2555-2555.	0.6	0
291	Impact Of The Pretreatment Characteristics As Well As Cyto- and Molecular-Genetic Profile On Outcome After Relapse In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 830-830.	0.6	0
292	Treatment Results In Acute Myeloid Leukemia Over a Time Period Of 20 Years: Analysis Of The German-Austrian Acute Myeloid Leukemia Study Group (AMLSCG). <i>Blood</i> , 2013, 122, 3878-3878.	0.6	0
293	An Adapted Gating Strategy Integrating a Myelomonocytic Window Is Necessary For Correct Flow Cytometric Diagnosis In a Large Proportion Of AML With Mutated NPM1. <i>Blood</i> , 2013, 122, 2593-2593.	0.6	0
294	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSCG). <i>Blood</i> , 2013, 122, 1332-1332.	0.6	0
295	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1314-1314.	0.6	0
296	Pomalidomide In MPN-associated Myelofibrosis With Cytopenia: Results Of The Mpns01-09 Study. <i>Blood</i> , 2013, 122, 2822-2822.	0.6	0
297	TP53 Mutations Detected By Next-Generation Deep-Sequencing In Patients With Myelodysplastic Syndrome and Isolated Deletion (5q): Results From a German Multicenter Trial. <i>Blood</i> , 2013, 122, 2759-2759.	0.6	0
298	Prospective Phase III Trial Of Valproic Acid (VPA) In Combination With All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy For AML In Older Patients: Final and Molecular Subset Analyses Of The AMLSCG 06-04 Study. <i>Blood</i> , 2013, 122, 3927-3927.	0.6	0
299	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSCG). <i>Blood</i> , 2014, 124, 1254-1254.	0.6	0
300	ABC1 Expression in Acute Myeloid Leukemia (AML): A Possible Predictive Value for Treatment Resistance?. <i>Blood</i> , 2014, 124, 3618-3618.	0.6	0
301	Cost-Effectiveness Analysis of Arsenic Trioxide in Combination with All-Trans Retinoic Acid in Acute Promyelocytic Leukemia with Pretreatment White Blood Counts $\leq 10^9/L$. <i>Blood</i> , 2014, 124, 2636-2636.	0.6	0
302	A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial. <i>Blood</i> , 2014, 124, 1918-1918.	0.6	0
303	NPM1 Splice Variant R2 Reveals Biological and Clinical Consequences of Prognostic Value in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 2338-2338.	0.6	0
304	Clinical Impact of TP53 Mutations in Patients with MDS and Isolated Deletion 5(q) Treated with Lenalidomide: Results from the German Prospective Le-Mon-5 Trial. <i>Blood</i> , 2014, 124, 1920-1920.	0.6	0
305	A Phase 1b Study of Panobinostat in Combination with Idarubicin and Ara-C in Patients with High-Risk Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2553-2553.	0.6	0
306	Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome. <i>Blood</i> , 2015, 126, 4123-4123.	0.6	0

#	ARTICLE	IF	CITATIONS
307	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. Blood, 2015, 126, 224-224.	0.6	0
308	Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3844-3844.	0.6	0
309	Reduced Intensity Conditioning with Fludarabine, BCNU and Melphalan (FBM) for Allogeneic Hematopoietic Cell Transplantation in Elderly AML Patients: Factors Predicting Outcome. Blood, 2015, 126, 5523-5523.	0.6	0
310	Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSC). Blood, 2015, 126, 227-227.	0.6	0
311	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSC 17-10) Tj ETQq1 1 0.784314 rgbT /Overl	0.6	0
312	Activity of cabazitaxel in temozolomide refractory glioblastoma: Final results of a phase 2 study (C-GBM study; EudraCT 2013-001550-98 NCT 01866449).. Journal of Clinical Oncology, 2017, 35, 2056-2056.	0.8	0
313	Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide " an International Collaborative Study. Blood, 2018, 132, 80-80.	0.6	0
314	The Genes for Tissue Factor F3 and Nuclear Receptor 4A Are Down-Regulated in Early Death Acute Promyelocytic Leukemia Patients. Blood, 2018, 132, 3902-3902.	0.6	0
315	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSC). Blood, 2019, 134, 2740-2740.	0.6	0
316	Biomarkers of Response to Romiplostim in Patients with Lower-Risk Myelodysplastic Syndrome (MDS) and Thrombocytopenia - Results of the Europe Trial By the Emsco Network. Blood, 2019, 134, 2998-2998.	0.6	0
317	Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4. Blood, 2021, 138, 1307-1307.	0.6	0